Extended Data Figure 10: δ-cell dedifferentiation in adult mice upon transient FoxO1 inhibition.

a–d, The 1 week FoxO1 inhibition with the compound AS1842856 in control unablated adult mice (a) results in dedifferentiation of one-fourth of the δ-cell population (b; Supplementary Table 30) (treated: n = 3, 1,347 YFP⁺-cells scored; untreated: n = 4, 1,224 YFP⁺-cells scored; error bars show s.d.), without leading to insulin (c; Supplementary Table 31) (treated: n = 3, 3,249 insulin⁺-cells scored; untreated: n = 4, 9,562 insulin⁺-cells scored; error bars show s.d.; Welch’s test (P = 0.1590)) or glucagon (d; Supplementary Table 32) (treated: n = 2, 728 YFP⁺-cells scored; error bar show s.e.m.) expression. e, One month following FoxO1 transient inhibition in β-cell-ablated adults, dedifferentiated δ-cells do not express glucagon (Supplementary Table 36) (treated: n = 2, 986 YFP⁺-cells scored; error bars show s.e.m.). f, Transient FoxO1 inhibition a long time (1 month) after β-cell ablation also leads to the appearance of lineage-traced dedifferentiated δ-cells that express insulin (Supplementary Tables 37–39) (treated: n = 3, 71 islets scored; 300 insulin⁺-cells scored; 1,216 YFP⁺-cells scored; error bars show s.d.). Scale bars, 20 µm.